sPARK.
2025

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Nature Medicine 31(2), 466–477

sPARK LabWungki Park
KRASGenomicsPDACPrognosis
79Citations
2025Year

Research Programs

ProgramKRAS-driven Vulnerabilities

Related by topic

Publication · KRAS, PDAC, GenomicsDistinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancerPublication · Genomics, PDACAlterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinomaResearch Program · KRAS, GenomicsBiliary Tract CancerProject / Trial · KRAS, PDACDaraxonrasib (RMC-6236)Publication · KRAS, PDACDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic CancerPublication · Genomics, PDACEarly-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Local graph

Drag to pan · scroll to zoom · drag a node to move · double-click to open

Open full graph →